Neurology
Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanaptâ„¢ in Mexico
July 11, 2011 6:33 am | by Bio-Medicine.Org | News | CommentsROCKVILLE, Md., July 11, 2011 /- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Probiomed S.A. de C.V.,...
Cancer Treatment Experts from Across Latin America Gather in Rio de Janeiro to Discuss Advances in Radiation Oncology
July 11, 2011 6:33 am | by Bio-Medicine.Org | News | CommentsRIO DE JANEIRO, July 11, 2011 /- Advances in radiotherapy for the treatment of cancer were among the many topics discussed during four days of scientific presentations at the Thirteenth Annual Congress of the Brazilian Society of Radiotherapy (SBRT), held in Rio de Janeiro last month....
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
July 8, 2011 1:36 am | by Bio-Medicine.Org | News | CommentsEAST HANOVER, N.J., July 8, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal...
Detecting "Lazy Eye" Earlier
July 7, 2011 8:35 am | by Bio-Medicine.Org | News | CommentsBOSTON, July 7, 2011 /PRNewswire-USNewswire/ -- A simple, seconds-long screening exam with a handheld scanning device may enable pediatricians to identify "lazy eye," a loss of vision in a structurally normal eye, in children as young as 2, report ophthalmologists at Children's Hospital...
Celldex makes Pepin new chief biz officer
July 6, 2011 10:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsCelldex Therapeutics Inc., a brain cancer vaccine developer in Needham, has named Ronald Pepin, formerly of Shire Pharmaceuticals and Medarex, as senior vice president and chief business officer of the company.
EHE International Showcases The National Tourette Syndrome Association, Inc. with Month-Long Window Display in Rockefeller Center Plaza
July 5, 2011 5:34 am | by Bio-Medicine.Org | News | CommentsNEW YORK, July 5, 2011 /PRNewswire-USNewswire/ -- The national Tourette Syndrome Association, Inc., (TSA) has unveiled a 115-square foot display window in 10 Rockefeller Plaza, created to generate awareness and acceptance of all people living with the much misunderstood neurological...
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
July 1, 2011 5:35 am | by Bio-Medicine.Org | News | CommentsALISO VIEJO, Calif., July 1, 2011 /- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and...
EMD Serono, Fast Forward award $1M in MS research grants
June 30, 2011 7:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsRockland biotech EMD Serono Inc. and Fast Forward LLC, a National Multiple Sclerosis Society-created nonprofit organization, are awarding more than $1 million in funding to a second group of three research projects focused on early-stage MS drug discovery research.
UCB Launches Research Alliance with Harvard University
June 30, 2011 5:35 am | by Bio-Medicine.Org | News | CommentsBOSTON and BRUSSELS, June 30, 2011 /- UCB and Harvard University officially launched their innovative Research Alliance during a signing ceremony that took place in Boston last night in the presence of his Royal Highness Prince Philippe of Belgium. (Photo:...
Bioengineers expanding work to solve cardiovascular health challenges
June 29, 2011 3:33 am | by Arizona State University | News | CommentsThree ASU bioengineers will expand their research into treatment of brain aneurysms and cardiovascular ailments with support from the American Heart Associationread more
Sanofi Pasteur Commends Winners of International BioGENEius Challenge
June 28, 2011 10:36 am | by Bio-Medicine.Org | News | CommentsSWIFTWATER, Pa., June 28, 2011 /- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY ), offers its congratulations to the four winners of the International BioGENEius Challenge, a competition for high school students who demonstrate an exemplary understanding of...
IBM Study Identifies New Generation of Connected Health Devices
June 28, 2011 7:37 am | by IBM | News | CommentsConsumers have a growing appetite for health and wellness devices, and this represents a burgeoning market opportunity for device manufacturers that has barely been tapped, according to a study from IBM (NYSE: IBM). The company also unveiled a list of possible wellness device innovations...
EnVivo begins Phase 1 Alzheimer's drug trial
June 27, 2011 10:36 am | by Mass High Tech: The Journal of New England Technology | News | CommentsEnVivo Pharmaceuticals Inc. of Watertown, which focuses on central nervous system therapies, said it has started a Phase 1 trial of its EVP-0962 Alzheimer's drug candidate in healthy volunteers.
MHT's Emerging Technology Forum looks at Superhero tech
June 24, 2011 10:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsFrom tabletop collaboration tools to brain control of remote devices and a powerful exoskeleton, innovators provided a glimpse into the future today during Mass High Tech's Emerging Technology Forum at Microsoft's NERD Center in Cambridge.
Elekta's Leksell Gamma Knife Perfexion is Ranked 2011's Best in KLAS for Radiation Therapy
June 24, 2011 6:34 am | by Bio-Medicine.Org | News | CommentsATLANTA, June 24, 2011 /- Elekta's Leksell Gamma Knife® Perfexion™ earned the number one ranking in the KLAS research firm's recently released 2011 Top 20 Best in KLAS Awards: Medical Equipment & Infrastructure* report. Perfexion received Best in KLAS in the radiation...
Aoxing Pharmaceutical Company Has No Comment on Unusual Trading Activity
June 23, 2011 12:35 pm | by Bio-Medicine.Org | News | CommentsJERSEY CITY, N.J., June 23, 2011 /- Aoxing Pharmaceutical (NYSE Amex: AXN ) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, reported that in light of the unusual market...
Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS)
June 23, 2011 6:47 am | by Bio-Medicine.Org | News | CommentsANN ARBOR, Mich., June 23, 2011 /- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN ), a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical...
13D Amendment Filed for RepliGen Corporation
June 23, 2011 4:41 am | by Bio-Medicine.Org | News | CommentsCHICAGO, June 23, 2011 /- Mr. Ronald L. Chez, a private investor, filed an amended 13D for RepliGen Corporation (Nasdaq: RGEN ) with the SEC. RepliGen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that...
A First Step Toward a Prosthesis for Memory
June 22, 2011 8:40 pm | by Massachusetts Institute of Technology | News | CommentsA neural implant helps rats with short-term recall.
Mr. Ronald L. Chez Filed Amended 13D for RepliGen Corporation
June 22, 2011 7:36 am | by Bio-Medicine.Org | News | CommentsCHICAGO, June 22, 2011 /- Amended 13D for RepliGen Corporation was filed with the SEC by Mr. Ronald L. Chez, a private investor. Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and a private investor. RepliGen Corporation is a biopharmaceutical company focused on building an...
Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression
June 22, 2011 5:33 am | by Bio-Medicine.Org | News | CommentsEVANSTON, Ill., June 22, 2011 /- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13. GLYX-13, a Glycine-site...
Cancer vaccines make progress in combating disease
June 21, 2011 8:36 pm | by Mass High Tech: The Journal of New England Technology | News | CommentsSen. Edward Kennedy's death two years ago from the deadly form of brain cancer, glioblastoma multiforme, refocused attention on how slowly treatments have progressed since former President Richard Nixon declared the war on cancer in 1971. But a new form of treatment that goes beyond...
Next-Generation Pharmacistâ„¢ Awards Program Announces 2011 Finalists
June 21, 2011 11:41 am | by Bio-Medicine.Org | News | CommentsDURHAM, N.C., June 21, 2011 /- Parata Systems and Pharmacy Times have announced the finalists for the second annual Next-Generation Pharmacist awards. The 2011 program, honoring pharmacists who define the future of the industry across a wide range of practice settings, attracted nearly...
New Study Explores Impact of More Uniform Distribution of Endovascular Coils in Cerebral Aneurysm Treatment
June 21, 2011 10:43 am | by Bio-Medicine.Org | News | CommentsRAYNHAM, Mass., June 21, 2011 /- A new study published in the June edition of the Journal of NeuroInterventional Surgery(1) highlights that a more uniform distribution of endovascular coils may help in the treatment of cerebral aneurysms, it was reported by Codman & Shurtleff, Inc....
U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries
June 21, 2011 7:45 am | by Bio-Medicine.Org | News | CommentsSAN FRANCISCO, June 21, 2011 /- Brain Plasticity Inc. (BPI), a technology incubator dedicated to the discovery and development of novel technologies that harness the basic principles of brain plasticity to improve the lives of people with neurological and psychiatric disorders, was...
